Trial · NCT03822832
Participant flow18
How many started, completed or left each group, period by period.
1 to 18 of 18
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Period 1 - Double Blind Period | STARTED | Placebo Intravenous Every 4 Weeks | 18 | |
| Period 1 - Double Blind Period | STARTED | Spesolimab 600 mg Intravenous Every 4 Weeks | 33 | |
| Period 1 - Double Blind Period | COMPLETED | Placebo Intravenous Every 4 Weeks | 8 | |
| Period 1 - Double Blind Period | COMPLETED | Spesolimab 600 mg Intravenous Every 4 Weeks | 22 | |
| Period 1 - Double Blind Period | NOT COMPLETED | Placebo Intravenous Every 4 Weeks | 10 | |
| Period 1 - Double Blind Period | NOT COMPLETED | Spesolimab 600 mg Intravenous Every 4 Weeks | 11 | |
| Re-allocation | STARTED | Placebo Intravenous Every 4 Weeks | 8 | |
| Re-allocation | STARTED | Spesolimab 600 mg Intravenous Every 4 Weeks | 22 | |
| Re-allocation | COMPLETED | Placebo Intravenous Every 4 Weeks | 6 | |
| Re-allocation | COMPLETED | Spesolimab 600 mg Intravenous Every 4 Weeks | 16 | |
| Re-allocation | NOT COMPLETED | Placebo Intravenous Every 4 Weeks | 2 | |
| Re-allocation | NOT COMPLETED | Spesolimab 600 mg Intravenous Every 4 Weeks | 6 | |
| Period 2 - Open Label Period | STARTED | Placebo Intravenous Every 4 Weeks | 6 | |
| Period 2 - Open Label Period | STARTED | Spesolimab 600 mg Intravenous Every 4 Weeks | 16 | |
| Period 2 - Open Label Period | COMPLETED | Placebo Intravenous Every 4 Weeks | 5 | |
| Period 2 - Open Label Period | COMPLETED | Spesolimab 600 mg Intravenous Every 4 Weeks | 13 | |
| Period 2 - Open Label Period | NOT COMPLETED | Placebo Intravenous Every 4 Weeks | 1 | |
| Period 2 - Open Label Period | NOT COMPLETED | Spesolimab 600 mg Intravenous Every 4 Weeks | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03822832/flow